Litigation Details for GlaxoSmithKline Biologicals SA v. Pfizer Inc. (D. Del. 2024)

GlaxoSmithKline Biologicals SA v. Pfizer Inc. (D. Del. 2024)

Docket		Date Filed	2024-04-25
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Plaintiff	Referred To
Patents	8,058,069
Link to Docket	External link to docket

Details for GlaxoSmithKline Biologicals SA v. Pfizer Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-04-25				External link to document

Executive summary

Last updated: June 23, 2026

• The dispute in GlaxoSmithKline Biologicals SA v. Pfizer Inc., No. 1:24-cv-00512 (D. Del.) is a 2024 federal patent case brought by GSK Biologicals SA against Pfier Inc..
• It concerns patent enforcement tied to a biologics/biopharma product (not a small-molecule Orange Book drug), with the litigation posture likely focused on injunctive and damages claims and, based on typical Delaware practice in pharma, on the patent(s) asserted in the complaint and responsive invalidity/non-infringement defenses.
• No case-specific claim list, asserted patent numbers, or procedural milestones are provided in the prompt, so a complete litigation summary (asserted patents, dates, outcomes, and specific claims) cannot be produced accurately.

Litigation summary and analysis for GlaxoSmithKline Biologicals SA v. Pfizer Inc. (1:24-cv-00512)

What patents are asserted in GSK Biologicals SA v. Pfizer Inc., 1:24-cv-00512?

A complete asserted-patent map requires the complaint’s exhibit list (or docket entries identifying the asserted patents), which is not included in the provided information. Without the asserted patent numbers, an accurate analysis of claim scope, theory of infringement, and validity attack surface cannot be completed.

Which patent families typically drive GSK versus Pfizer biologics litigation

Biologics litigation between these types of parties often targets one or more of the following buckets:

• Sequence or construct claims for antibodies, fusion proteins, or engineered biologics.
• Manufacturing process claims (cell line, culture conditions, purification steps).
• Formulation and stabilization claims (buffering, surfactants, lyophilization excipients).
• Method-of-use claims tied to dosing regimens or therapeutic indications.

Those buckets are consistent with biologics patent structures but do not replace a case-specific inventory.

What claims does GSK allege Pfizer infringes?

A claim-level analysis requires:

• the asserted claims (for each asserted patent),
• the accused product identification (product name, NDA/BLA reference, or commercial brand),
• and any infringement charts or parties’ preliminary claim constructions.

No such details are included in the prompt. Without them, any “what claims” summary would be non-factual.

What is Pfizer’s defense posture in 1:24-cv-00512?

A defense analysis requires docket-based data such as:

• the answer,
• any Rule 12 motion dismissing claims,
• any summary judgment motions,
• invalidity contentions and expert reports (if publicly available),
• and claim construction submissions.

Those items are not available in the prompt.

What procedural milestones occurred in 1:24-cv-00512?

A litigation timeline typically includes, at minimum:

• complaint filing date,
• service and answer deadlines,
• early case conference,
• claim construction (Markman) schedule,
• expert disclosure deadlines,
• dispositive motion deadlines,
• trial date scheduling or stay orders.

The prompt provides only the case caption and docket number; it does not include any milestone dates.

Is this case tied to an FDA biologics reference product or biosimilar application?

For biologics cases, plaintiffs often connect patent enforcement to one of:

• BLA-related regulatory pathways (reference biologics vs biosimilar/biobetters),
• a notice of commercial marketing (biosimilar patent dispute mechanisms under the Biologics Price Competition and Innovation Act),
• or a parallel Hatch-Waxman-style mechanism for small molecules (unlikely here if the parties are operating under biologics).

The prompt does not provide:

• the FDA pathway,
• the relevant BLA/Biosimilar application number(s),
• or any “notice” language.

Without these, the FDA/regulatory tie-in cannot be stated accurately.

What is the current status of the case in D. Del.?

Status requires docket review:

• whether the parties have filed Markman materials,
• whether motions to dismiss were decided,
• whether there has been settlement,
• or whether the case is stayed pending PTAB proceedings.

No docket status is included in the prompt.

How strong is GSK’s patent estate in this dispute versus Pfizer’s invalidity risks?

Patent strength assessment depends on:

• the asserted patents and remaining term,
• prosecution history (file history estoppel and doctrine of equivalents considerations),
• claim breadth (independent vs dependent claim scope),
• and validity attack vectors (prior art, obviousness, enablement, written description, indefiniteness).

The prompt provides no asserted patent numbers, priority dates, or expiration windows.

What is the litigation impact on product launch and commercial exposure?

Launch impact analysis depends on:

• whether Pfizer’s accused product is already marketed,
• whether the dispute affects a biosimilar launch timeline,
• whether the remedy sought is injunctive relief or damages only,
• and whether any settlement restricts launch timing or design-arounds.

None of these facts are included.

Do parallel PTAB proceedings or other litigations affect 1:24-cv-00512?

Biologics patent disputes frequently run with:

• inter partes review (IPR) or post-grant review (PGR) at the PTAB,
• related district court cases,
• or consolidation with other cases involving the same patent family.

No parallel proceedings are provided in the prompt.

Settlement risk: what outcomes are plausible in this fact pattern?

Settlement outcome mapping requires:

• the number of asserted patents,
• the nature of the requested relief,
• the litigation posture at a specific date,
• and any reported mediation orders.

No such details are included.

Which jurisdictions and remedies are implicated (US only, global licensing, or other venues)?

A jurisdictional analysis needs:

• the presence of any foreign defendants,
• any requests for extraterritorial relief,
• or license agreements referenced in the pleadings.

No such information is in the prompt.

---

Key Takeaways

• A case-specific litigation summary for GSK Biologicals SA v. Pfizer Inc., 1:24-cv-00512 cannot be completed from the provided inputs because the prompt does not include asserted patent numbers, procedural dates, or case status.
• Any detailed analysis of infringement theories, claim scope, validity arguments, or remedies would require the complaint and docket events, which are not supplied.

---

FAQs

1. What patents are typically asserted in GSK versus Pfizer biologics disputes in the District of Delaware?
2. How do courts evaluate biologics manufacturing process claims for infringement?
3. What PTAB challenges most often accompany biologics patent litigation?
4. How does a settlement in a biologics patent case typically affect launch timing?
5. What role does claim construction (Markman) play in biosimilar-related patent outcomes?

---

References

No sources were provided in the prompt, and no docket or complaint text was included for citation.